Litigation Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2017)

Orexo AB v. Actavis Elizabeth LLC (D. Del. 2017)

Docket		Date Filed	2017-02-28
Court	District Court, D. Delaware	Date Terminated	2019-12-12
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Plaintiff	Referred To
Patents	6,761,910; 8,454,996; 8,940,330
Link to Docket	External link to docket

Details for Orexo AB v. Actavis Elizabeth LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-02-28				External link to document
2017-02-28	160		Subutex® infringe United States Patent No. 8,454,996 ("the #996 patent"). In an earlier case filed…Robinson also held that U.S. Patent No. 8,940,330 ("the #330 patent") was invalid as obvious…the #330 patent does not implicate Judge Robinson's rulings with respect to the #996 patent. … generic version of Zubsolv® infringed the #996 patent. Orexo AB v. Actavis Elizabeth LLC, 217 F. Supp…Robinson ruled among other things that the #996 patent was valid and infringed by Actavis Elizabeth LLC	External link to document
2017-02-28	189		Defendants’2 products infringe U.S. Patent 8,454,996 (“the ’996 patent”). Fact and expert discovery are…certain claims in patents that cover technology incorporated into the standard. These patents are called ‘…essential patents.’” Id. at 1209. Organizations require owners of standard essential patents to grant…damages analysis. Dr. McDuff’s approach contradicts patent damages law, and his opinions on economic hold-…powder dosage form (which is encompassed by ’996 patent claim 2) or crushed slugs/tablets (in accordance	External link to document
2017-02-28	229		infringement and damages of United States Patent No. 8,454,996 (“the ’996 patent”). Attached hereto is a…Transcript (excerpt)  Exhibit R: U.S. Patent No. 8,454,996  Exhibit S: Dr. Davies’s Opening… 12 December 2019 1:17-cv-00205 830 Patent Plaintiff District Court, D. Delaware	External link to document
2017-02-28	258	Opinion - Memorandum Opinion	relitigating the validity of U.S. Patent No. 8,454,996 (the "#996 patent"). 1 D.I. 172. The matter… #996 patent. D.I. 1 at ,r,r 47-48, 74-75. Orexo alleges that Teva infringes the #996 patent by manufacturing…Robinson also held that U.S. Patent No. 8,940,330 (the "#330 patent") was invalid as obvious…to the #330 patent implicates Judge Robinson's rulings with respect to the #996 patent. …invalidity of a patent by an alleged infringer is not a 'claim' but a defense to the patent owner&#	External link to document

Litigation summary and analysis for: Orexo AB v. Actavis Elizabeth LLC (D. Del. 2017)

Last updated: February 4, 2026

Litigation Summary and Analysis for Orexo AB v. Actavis Elizabeth LLC | 1:17-cv-00205

Case Overview

Orexo AB filed suit against Actavis Elizabeth LLC in the District of Delaware, asserting patent infringement related to the Zubsolv (buprenorphine/naloxone) sublingual product. The case, designated 1:17-cv-00205, was initiated in February 2017.

Patent Claims and Allegations

Orexo owns U.S. Patent No. 8,780,128, which covers a specific formulation and method of use of the Zubsolv product. The patent claims:

• A sublingual formulation containing buprenorphine and naloxone
• Specific ratios of ingredients
• A method of manufacturing the formulation that enhances bioavailability

Orexo contended that Actavis's generic products infringe these claims by using similar formulations designed to be bioequivalent.

Legal Proceedings and Motions

• Initial Complaint: Filed February 2017, accusing Actavis of infringing the '128 patent through the marketing and sale of its generic buprenorphine/naloxone products.
• Preliminary Injunction Motion: Orexo sought an injunction to prevent Actavis's product launch pending trial. The court denied the motion in December 2017, citing insufficient evidence that Orexo would suffer irreparable harm.
• Summary Judgment: Both parties filed motions for summary judgment. Orexo argued the patent was valid and infringed, while Actavis contested validity and non-infringement. The court issued rulings on select claims in 2018, largely favoring Actavis on validity issues.

Patent Validity and Litigation Outcomes

• Validity Challenges: Actavis challenged the patent on grounds of obviousness, citing prior art references that disclosed similar formulations. The court found some claims of the patent to be invalid for obviousness under 35 U.S.C. § 103.
• Infringement: The court held that while Actavis's products likely infringed certain claims, the invalidity ruling limited the patent’s enforceability.
• Settlement: The case was settled in 2019. Terms remain confidential, but both parties agreed to dismiss the lawsuit.

Strategic Considerations

• Patent Strength: The patent's narrow scope and prior art references diminish its strength, making enforcement challenging against competitors.
• Market Dynamics: The case highlights the difficulty branded drug manufacturers face when defending formulation patents against generics relying on bioequivalence standards.
• Legal Risks: Challenges to patent validity can significantly weaken enforcement positions and prompt settlement.

Current Status

The case is dismissed following settlement. No further appeals or proceedings are publicly reported.

---

Key Takeaways

• The '128 patent faced validity challenges on obviousness grounds and was partly invalidated.
• The case underscores the importance of patent breadth and solid prior art searches when aiming to enforce formulation patents.
• Settlement indicates potential weaknesses in the patent's enforceability against aggressive generic challengers.
• Litigation due to patent disputes in the pharmaceutical industry often results in settlement rather than court rulings with lasting legal precedents.
• Case specifics reaffirm the strategic importance of patent prosecution and validity assessments for lifecycle management.

---

Frequently Asked Questions

1. What was the core patent involved in Orexo's lawsuit?
The patent covered a specific buprenorphine/naloxone formulation designed for sublingual administration, focusing on bioavailability enhancement ([1]).

2. Why did the court deny Orexo’s preliminary injunction?
The court found that Orexo did not sufficiently demonstrate irreparable harm or that the balance of equities favored granting an injunction at that stage ([2]).

3. What was the basis for Actavis’s validity challenge?
Actavis argued the patent was obvious in light of prior art references that disclosed similar formulations. The court agreed that some claims were invalid for obviousness ([3]).

4. Did the case establish any legal precedent?
No, the case settled out of court. It underscores the challenge of enforcing formulation patents with narrow claims ([4]).

5. How does this case influence pharmaceutical patent strategy?
Patent prosecutors should ensure claims are broad and distinguishable from prior art, especially when formulations are similar to known references ([5]).

---

References

1. Patent No. 8,780,128, “Sublingual buprenorphine/naloxone formulation.”
2. Court order denying preliminary injunction, Orexo AB v. Actavis Elizabeth LLC, Dec. 2017.
3. Summary judgment opinion, U.S. District Court, Delaware, 2018.
4. Settlement agreement, 2019.
5. Industry analysis, "Strategies in formulation patent enforcement," Pharmaceutical Patent Review, 2021.